Ayobami Akenroye, MBChB MPH PhD
Brigham and Women’s Hospital, Inc.
Research Project:
Matching the Right Patient to the Right Medicine in Allergic and Eosinophilic Asthma
Grants Awarded:
- Allergic Respiratory Diseases Award
- American Lung Association/AAAAI Allergic Respiratory Diseases Research Award
Research Topics:
- biomarkers
- clinical research
- immunology immunotherapy
- proteomics
Research Diseases:
- allergy
- asthma
Patients with severe asthma account for a disproportionate share of asthma-related burden. Omalizumab and mepolizumab are biologic therapies approved for the treatment of asthma uncontrolled by conventional therapies. The two asthma phenotypes in patients with severe uncontrolled asthma often overlap: allergic (omalizumab) and eosinophilic asthma (mepolizumab). However, there are limited biomarkers to predict response to each of these biologics. Selection of the wrong biologic can be costly to both patients, given that asthma is potentially fatal, and to the healthcare system. We will identify proteins that predict response to each of these biologics and identify proteins that may differentiate a patient likely to respond to mepolizumab from one likely to respond to omalizumab. We have chosen proteins which we previously found were associated with inflammation in asthma and responded to biologic treatment. These studies will improve our ability to match the right patient to omalizumab or mepolizumab.
Co-Funded American Lung Association & Academy of Allergy, Asthma & Immunology
Page last updated: October 4, 2024
Double Your Support Now
Your gift will have 2X the impact this Lung Cancer Awareness Month.
